Page last updated: 2024-11-02

pioglitazone and Urinary Lithiasis

pioglitazone has been researched along with Urinary Lithiasis in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, Z1
Yuan, P1
Sun, X1
Tang, K1
Liu, H1
Han, S1
Ye, T1
Liu, X1
Yang, X1
Zeng, J1
Yan, L1
Xing, J1
Xiao, K1
Ye, Z1
Xu, H1
Yasui, T1
Okada, A1
Hamamoto, S1
Ando, R1
Taguchi, K1
Tozawa, K1
Kohri, K1

Reviews

1 review available for pioglitazone and Urinary Lithiasis

ArticleYear
Pathophysiology-based treatment of urolithiasis.
    International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:1

    Topics: Animals; Cardiovascular Diseases; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Disease Models, A

2017

Other Studies

1 other study available for pioglitazone and Urinary Lithiasis

ArticleYear
Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-γ-miR-23 axis.
    American journal of physiology. Renal physiology, 2019, 07-01, Volume: 317, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Binding Sites; Calcium Oxalate; Crystallization; Disea

2019